Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025 Share Dec 1, 2025 6:45 AM Eastern Standard Time Merck granted Fast Track Designation by the U.S. FDA for MK-2214 for the treatment of Alzheimer's disease RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced plans to present first-in-human data for MK-2214 and MK-1167 at Clinical Trials on Alzheimer's Disease (CTAD) 2025 in San Diego, California from Dec. ...